Cart
Your cart is empty
Find
Retatrutide · GIP / GLP-1 / glucagon triple agonist
Retatrutide (LY3437943), a 39-residue acylated peptide built to engage the GIP, GLP-1 and glucagon receptors at once. Supplied as a lyophilized powder for research purposes only.
Launch Sale · Ends Nov 6
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Reta — retatrutide, originally LY3437943 — pushes incretin chemistry one receptor further. Where the headline GLP-1 drugs hit one or two targets, this 39-residue acylated peptide is built to engage three at once: GIP, GLP-1, and glucagon. The fatty-acid chain is the durability piece; the three-way agonism is the design thesis.
The glucagon arm is what makes it distinct. Adding glucagon-receptor activity brings energy expenditure into play alongside the appetite and insulinotropic effects of the incretin side, so the compound is studied as a test of whether a single molecule can pull all three levers without the three working against each other.
The interesting question with Reta is balance: how potently it hits each of the three receptors and what the combined signal does that no single arm does alone. Studies parse the relative contributions of GIP, GLP-1, and glucagon activity to glycemic control, appetite, and energy expenditure, with body-weight and metabolic endpoints carrying most of the weight.
Functionally, Reta is one backbone wired to three incretin/glucagon receptors. The GLP-1 and GIP arms cover the insulinotropic and appetite-side pharmacology familiar from earlier analogues; the glucagon arm layers on a thermogenic, energy-expenditure component that the dual agonists lack.
The evidence base is unusually fast-moving for a research peptide. Coskun’s discovery paper laid out the tri-agonism, and the 2023 Jastreboff and Rosenstock Phase 2 trials read the combined receptor activity against body-weight and glycemic endpoints — the data most current work on this molecule is anchored to.
Retatrutide grew out of the multi-agonist program that followed tirzepatide. Once a GIP/GLP-1 dual agonist had proven out, the open question was whether glucagon-receptor activity could be folded into the same molecule, and LY3437943 was the candidate that carried that three-way design into testing.
Coskun’s discovery-to-proof-of-concept report established the tri-agonist profile; the trials that followed characterized it across diabetes and obesity cohorts, fixing its place in the literature as a single-peptide triple agonist.
In vitro and animal studies
Retatrutide (LY3437943) is a single synthetic peptide engineered to act as an agonist at three receptors simultaneously: GLP-1, GIP and glucagon. The design intent is explicit in the published chemistry — GLP-1 and GIP agonism drive insulinotropic and appetite effects, while glucagon receptor agonism adds energy expenditure, a component absent from dual agonists such as tirzepatide.
Preclinical work in rodent obesity models reported weight reduction exceeding that of comparator incretin agonists, with the additional loss attributed to the glucagon arm increasing energy expenditure rather than to further appetite suppression alone. Studies also describe reductions in hepatic steatosis, which is mechanistically consistent with glucagon receptor engagement in the liver.
The glucagon component is what makes retatrutide pharmacologically distinctive and also what makes it harder to predict. Glucagon receptor agonism raises hepatic glucose output, which is the opposite of what a glucose-lowering agent should do; the design depends on the incretin arms outweighing that effect. Balancing three receptor activities in one molecule is a genuine engineering achievement and a genuine source of uncertainty.
Human data, where it exists
Retatrutide has a real and unusually strong clinical record for a compound sold as a research chemical. A phase 2 randomised, double-blind, placebo-controlled trial in adults with obesity was published in the New England Journal of Medicine in 2023, reporting mean weight reduction of roughly 24 percent at 48 weeks at the highest dose studied — the largest figure reported for any pharmacological agent in a trial of that design at the time. Separate phase 2 work covered type 2 diabetes and knee osteoarthritis in obesity.
Phase 3 development under the TRIUMPH programme has been under way since. As of now retatrutide has no marketing approval from Health Canada, the FDA or the EMA for any indication, and the phase 3 efficacy and safety results that would support approval are not complete.
The trial data therefore establishes short-to-medium term efficacy in a controlled setting under medical supervision. It does not establish long-term safety, and it says nothing about material of unverified provenance used outside that setting.
Common assertions, and what the record supports
The claim that retatrutide produces greater weight reduction than semaglutide or tirzepatide is, unusually, supported by trial data — the phase 2 figures are higher than those reported in comparable trials of either. This is one of the few places in the research-peptide field where a strong marketing claim tracks a strong published result.
What does not follow is the inference commonly drawn from it. Phase 2 results are generated with pharmaceutical-grade material, a titration schedule designed to manage adverse effects, and monitoring for the effects that titration exists to catch. None of those conditions attach to research material, and the trial figures cannot be read as expected outcomes without them.
The second unsupported claim is safety by association with approved incretins. Retatrutide is not an approved incretin; it engages a receptor the approved agents do not, and its long-term safety profile is precisely what phase 3 is still measuring.
Against the compounds it is most often confused with
Retatrutide, tirzepatide and semaglutide form a clear progression in receptor coverage. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds a third arm, glucagon receptor agonism, which is the pharmacologically novel component: rather than further suppressing appetite, it is intended to raise energy expenditure. Reported phase 2 weight reduction follows that same order, with retatrutide highest.
The glucagon arm is also what makes retatrutide the least predictable of the three. Glucagon receptor agonism raises hepatic glucose output, so the net metabolic effect depends on the incretin arms outweighing it — a balance characterised only within studied dose ranges. Semaglutide, by contrast, has years of post-approval pharmacovigilance behind it.
Against the non-incretin metabolic compounds here — 5-Amino-1MQ and SLU-PP-332 — there is no mechanistic overlap whatsoever. Those act on NNMT and ERR respectively, intracellular targets, with no receptor agonism and no appetite component.
Adverse findings, toxicology gaps, material hazards
Reported adverse effects in the published trials were predominantly gastrointestinal — nausea, vomiting, diarrhoea and constipation — and were dose-dependent, which is why trial protocols escalate slowly. Dose-dependent increases in heart rate were also reported, a finding that warrants attention and that the glucagon component makes mechanistically plausible.
The class carries a rodent thyroid C-cell tumour signal, which is the basis of the boxed warning on approved GLP-1 receptor agonists and the contraindication in medullary thyroid carcinoma and MEN2. Pancreatitis and gallbladder events are recognised class concerns. Loss of lean mass alongside fat mass is a documented feature of rapid weight reduction with these agents.
Because glucagon receptor agonism raises hepatic glucose output, the metabolic effect of this compound is a net of opposing actions — a balance that has been characterised only within the dose ranges and populations studied.
Materially, retatrutide is a long and complex synthetic peptide, difficult and expensive to manufacture correctly. It is among the compounds where independent identity confirmation matters most, because incorrect or degraded material is not merely weaker but pharmacologically different.
Bench practice for this compound
Retatrutide ships lyophilized. Reconstitute with bacteriostatic water introduced slowly against the vial wall; peptides of this length are particularly prone to aggregation and foaming, and mechanical agitation is the fastest way to destroy the material. Swirl gently until the cake dissolves and do not shake under any circumstances.
Hold reconstituted vials at 2–8 °C, protected from light, and treat the stated window as a limit rather than a target. Keep unopened lyophilized powder frozen for long-term storage, and avoid freeze-thaw cycling of material in solution. Our peptide calculator converts vial strength and diluent volume into concentration per unit volume.
This summary describes published research. It is not a protocol, not a recommendation, and not a statement that this compound is safe or effective for any use. Not for human or animal use.
Jastreboff, A.M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514–526.
PubMedCoskun, T. et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34(9):1234–1247.e9.
PubMedRosenstock, J. et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529–544.
PubMedJanah, L. et al. (2019). Glucagon Receptor Signaling and Glucagon Resistance. Int J Mol Sci 20(13):3314.
PubMedFinan, B. et al. (2015). Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 418 Pt 1:42–54.
PubMedEvery lot is tested for identity, purity, and net content.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%, on the lot you receive.
Same Shelf
